For patients undergoing plastic surgery procedures, there's no consistent evidence that taking antidepressants increases the risk of bleeding, breast cancer, or other adverse outcomes, concludes a research review in the November issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
Stopping antidepressants before plastic and reconstructive surgery is unlikely to reduce complications—and might increase the risk of postoperative problems related to the patient's underlying depression, according to the report by Dr. Isabel Teo of Ninewells Hospital, Dundee, and medical student Christopher Tam Song of University of Edinburgh.
Do Antidepressants Increase Complications after Plastic Surgery?
Antidepressant use has increased in recent years, with one study reporting that 1 out of 10 US adults and adolescents use these medications. Rates of antidepressant use may be even higher among patients undergoing cosmetic plastic surgery, or patients with breast cancer undergoing breast reconstruction.
While plastic surgeons are alert for use of medications that might increase complications, such as blood thinners, they are typically not concerned about antidepressants. Dr. Teo and Mr. Song performed an in-depth review of research data on the risks of antidepressant treatment in plastic surgery. They analyzed 26 studies assessing the effects of antidepressants on various plastic surgery risks, including:
Bleeding. Six studies assessed the impact of antidepressants and bleeding risk in more than 34,000 patients undergoing breast cancer surgery and 2,500 undergoing cosmetic plastic surgery. The results were inconsistent: while some studies found increased bleeding rates in patients taking antidepressants, others found no such risk.
So while the evidence doesn't rule out an increase in bleeding risk, stopping antidepressants before surgery—especially the widely used selective serotonin reuptake inhibitors (SSRIs)—might worsen depression symptoms or lead to a potentially disastrous "discontinuation syndrome." The authors conclude, "Therefore, routine discontinuation of antidepressants before surgery in the absence of a careful evaluation should be avoided."
Breast cancer risk. Six reports—mainly large meta-analyses of previous data—examined the risk of breast cancer among patients taking antidepressants. Again, the results were conflicting: some reviews found a "modest" increase of breast and ovarian cancer among antidepressant users while others found no relationship.
Breast cancer outcomes. Six studies including more than 11,000 patients examined whether antidepressants might interfere with tamoxifen—a drug used to lower the risk of recurrent breast cancer. Most studies found no evidence that this drug combination increased the risk of recurrent breast cancer. However, there was a possible interaction between tamoxifen and one specific antidepressant—the potent SSRI paroxetine.
Breast enlargement. One study of 59 patients suggested a possible increase in the risk of breast enlargement and pain among women taking SSRIs. However, most patients with breast enlargement also had weight gain—a known side effect of SSRI use.
A handful of studies looked at various other complications. One reported an increased risk of seromas (fluid collections) after plastic surgery in patients taking SSRIs. Another reported a possible interaction between SSRIs and methylene blue dye used for lymph node mapping in patients with breast cancer.
While acknowledging the limitations of the available data, Dr. Teo and Mr. Song note their review finds no consistent evidence of increased complications related to antidepressants. The risks of stopping prescribed antidepressant therapy in "psychologically vulnerable" patients likely outweigh any increase in complications.
However, plastic surgeons should consider the impact of the underlying depressive symptoms in patients taking these medications, the authors believe. They conclude, "The use of antidepressants for mental disorders may also implicate key patient risk factors for surgical complications and sufficient exploration into the patient's indications for the prescription is crucial."
Article: "Assessing the Risks Associated with Antidepressant Use in Plastic Surgery: A Systematic Review" (doi: 10.1097/PRS.0000000000001696)
Plastic and Reconstructive Surgery
For more than 60 years, Plastic and Reconstructive Surgery® ( http://journals.lww.com/plasreconsurg/) has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. You can learn more and visit the American Society of Plastic Surgeons at www.plasticsurgery.org or www.facebook.com/PlasticSurgeryASPS and www.twitter.com/ASPS_news.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.